TSE:4523Pharmaceuticals
Is Eisai (TSE:4523) Cheap After China Approved At Home Leqembi Dosing?
Eisai (TSE:4523) is back in focus after China’s National Medical Products Administration approved the Leqembi subcutaneous autoinjector as an initiation treatment for early Alzheimer’s disease, opening a new at home dosing option.
The China approval arrives after a recent string of Leqembi related milestones, including progress on subcutaneous dosing in the US and a reimbursement recommendation in Canada. It comes as Eisai’s share price return is positive over the past quarter, while the 5...